Related Experiment Video

Updated: Oct 24, 2026

Intravenous Injections in Neonatal Mice
05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

The use of prophylactic intravenous immunoglobulin therapy in very low birthweight infants

Y H Chou1, K I Yau

  • 1Division of Neonatology, Chang Gung Children's Hospital, Taipei, Taiwan, R.O.C.

Changgeng Yi Xue Za Zhi
|March 13, 1999
PubMed

Insights

Prophylactic intravenous immunoglobulin (IVIG) therapy in very low birthweight (VLBW) infants increased immunoglobulin G (IgG) levels but did not reduce hospital-acquired infections. Further research is needed to confirm its efficacy in preventing infections in VLBW infants.

Area of Science:

  • Neonatalogy
  • Immunology
  • Infectious Diseases

Background:

  • Nosocomial infections are a significant cause of mortality in premature infants, particularly those with very low birthweight (VLBW).
  • VLBW infants exhibit low serum immunoglobulin G (IgG) levels, increasing susceptibility to early infancy infections.
  • Prophylactic intravenous immunoglobulin (IVIG) administration is explored to elevate IgG levels and mitigate hospital-acquired infections.

Purpose of the Study:

  • To evaluate the efficacy of prophylactic IVIG therapy in VLBW infants.
  • To determine if IVIG administration can maintain higher IgG levels and reduce hospital-acquired infection rates.
  • To assess the impact of IVIG on the timing of the first documented sepsis episode.

Main Methods:

  • A randomized controlled study involving 61 VLBW infants, divided into IVIG (n=31) and control (n=30) groups.
  • IVIG group received 500-1000 mg/kg doses every 2 weeks; control group received saline infusion.
  • Infusions continued until infants reached 1800g or were discharged.

Main Results:

  • No significant differences in perinatal and neonatal characteristics between groups.
  • IVIG group consistently demonstrated higher serum IgG levels.
  • The age of the first documented sepsis was earlier in the control group compared to the IVIG group.

Conclusions:

  • Prophylactic IVIG therapy effectively increases IgG levels in VLBW infants, with sustained elevation for up to 2 months.
  • The study did not observe a significant prophylactic effect of IVIG in reducing hospital-acquired infections.
  • While IVIG impacts IgG levels, its role in preventing infections in VLBW infants requires further investigation.
Abstract

More Related Videos

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells06:32

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells

Published on: June 26, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.